US.WST · West Pharmaceutical Services

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.0335462109109907,
        "turnoverUsdM": 126.50835277785599,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.WST",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 332.0142,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.1,
      "take_profit_price": 363.3945,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2293794881996052,
    "stopLossPercent": 4.0670924218219815,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 54.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 349.6685,
    "ma50": 349.36,
    "close": 346.09,
    "prevClose": 349.92,
    "avgVolume20": 502027,
    "volumeRatio": 0.73,
    "changePercent": -1.09
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.021709003638211377,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.7140142007442206,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.8651537100559693,
      "volat_points": 0,
      "day_range_pct": 0.017220931170746696,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 54.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 17.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59.67,
        "contribution": 17.9
      },
      {
        "raw": 8,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 53.7,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 17.9/30分",
      "情緒分析: 8/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.2,
      "資金流": 6.8,
      "市場環境": 8.6,
      "情緒分析": 8,
      "技術信號": 17.9,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 126.50835277785599,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.WST",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 716.5175022500002,
                "ma50": 712.1846009999998,
                "name": "QQQ",
                "close": 721.059998,
                "points": 2
              },
              "spy": {
                "ma20": 768.0999969500001,
                "ma50": 753.38740206,
                "name": "SPY",
                "close": 771.099976,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.0335462109109907,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "sentiment": {
            "score": 8,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 7,
              "sentimentScoreRaw": 2.1
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141283987,
                "url": "https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...",
                "category": "company",
                "datetime": 1787263752,
                "headline": "West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786738980,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141283980,
                "url": "https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1786726803,
                "headline": "West Pharmaceutical (WST) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141202470,
                "url": "https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...",
                "category": "company",
                "datetime": 1786518635,
                "headline": "West (WST) Stock Looks Overvalued After A 47% One Year Run"
              },
              {
                "id": 141135724,
                "url": "https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]",
                "category": "company",
                "datetime": 1786024529,
                "headline": "Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"
              }
            ],
            "raw_source": [
              {
                "id": 141283982,
                "url": "https://finnhub.io/api/news?id=c4b2da463c6f09a31ce8e17d294cbf1644931a45b43de4a4e12c8f1e77ee8f38",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.",
                "category": "company",
                "datetime": 1787330760,
                "headline": "Here's Why You Should Retain Inogen Stock in Your Portfolio for Now"
              },
              {
                "id": 141278125,
                "url": "https://finnhub.io/api/news?id=c4219d4c8cc06018c3099f6575c54f4f5c3fca8777f4943262f105bf447c2dec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update"
              },
              {
                "id": 141283984,
                "url": "https://finnhub.io/api/news?id=b75563b5894b58e0887a3679e9fdda1971893a4221c73767729b846b337b105a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.",
                "category": "company",
                "datetime": 1787330040,
                "headline": "INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141283985,
                "url": "https://finnhub.io/api/news?id=b73e213a06b8ca1cf8c2e1fb47c041c4ea799d097e88e7a558e805c84d3ec268",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.",
                "category": "company",
                "datetime": 1787329800,
                "headline": "BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141279656,
                "url": "https://finnhub.io/api/news?id=5f941718a2b3dcd6c642c392d28f14263bd1e17229ca84c001ef41096bad7251",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.",
                "category": "company",
                "datetime": 1787328720,
                "headline": "Here's Why You Should Hold Stryker Stock in Your Portfolio for Now"
              },
              {
                "id": 141283987,
                "url": "https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...",
                "category": "company",
                "datetime": 1787263752,
                "headline": "West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141283989,
                "url": "https://finnhub.io/api/news?id=06ef2c3b0c310a88b2928dc5b444a63ea76f2997d316a233b82b79a982d0782e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.",
                "category": "company",
                "datetime": 1787246340,
                "headline": "Here's Why You Should Add INSP Stock to Your Portfolio Now"
              },
              {
                "id": 141266860,
                "url": "https://finnhub.io/api/news?id=db611a64fbf03b230be4b5b782e1bab7a0378c9f276b9bc20f8b0c7c17ff967e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.",
                "category": "company",
                "datetime": 1787246040,
                "headline": "MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor"
              },
              {
                "id": 141271747,
                "url": "https://finnhub.io/api/news?id=a411d7c50ee1158e49ad68a8649589e2aaab44386f5c689d45e85d64c9b6f354",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.",
                "category": "company",
                "datetime": 1787162160,
                "headline": "SNN Advances Surgical Robotics Through Imperial College Partnership"
              },
              {
                "id": 141283992,
                "url": "https://finnhub.io/api/news?id=37eb4fb3fb259704bc8889e42d9c66402dc8110e9f56566c62af937ffc38bd2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.",
                "category": "company",
                "datetime": 1787162100,
                "headline": "HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141279330,
                "url": "https://finnhub.io/api/news?id=30e482ac66f335fd06f9335323ecea233f86b3fec37689483b7273b323f2c7d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.",
                "category": "company",
                "datetime": 1787161080,
                "headline": "Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific"
              },
              {
                "id": 141283994,
                "url": "https://finnhub.io/api/news?id=7118fcfc455dcfff25cf8dd09c68938daf08dd78c9ed045f17f2c2487c7c2d8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.",
                "category": "company",
                "datetime": 1787152500,
                "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now"
              },
              {
                "id": 141250273,
                "url": "https://finnhub.io/api/news?id=4f4d8cd3325945129135da552aa9f2af17f3d76a9331ac1cf5b18cfb4c48d155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.",
                "category": "company",
                "datetime": 1787068920,
                "headline": "Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery"
              },
              {
                "id": 141250274,
                "url": "https://finnhub.io/api/news?id=1a975a5def559bb06a4ecfcda3aecee05a660ede0187e55aaffd5aa1794c5c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.",
                "category": "company",
                "datetime": 1786997100,
                "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio Now"
              },
              {
                "id": 141250275,
                "url": "https://finnhub.io/api/news?id=72aa3033993c9773bbace7800f1af4af161f6496b542780f6d21fdea95613697",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.",
                "category": "company",
                "datetime": 1786985040,
                "headline": "Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786738980,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141283980,
                "url": "https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1786726803,
                "headline": "West Pharmaceutical (WST) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141250277,
                "url": "https://finnhub.io/api/news?id=4d66f96c7426611bc85ae63ebd3054a79571355183b4b1651d55d3f64e7b113d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.",
                "category": "company",
                "datetime": 1786723500,
                "headline": "iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141202468,
                "url": "https://finnhub.io/api/news?id=d0e7e846d43e052f5cf2cc75222b2e19cdf44371cf038926785d5e1b34db15a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.",
                "category": "company",
                "datetime": 1786549260,
                "headline": "Here's Why You Should Add BrightSpring Stock to Your Portfolio Now"
              },
              {
                "id": 141202469,
                "url": "https://finnhub.io/api/news?id=e0277f3fb832d7629b5cfa40809a7c12d4b0dd92ab901d8e20bba9889d3940ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.",
                "category": "company",
                "datetime": 1786548120,
                "headline": "NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up"
              },
              {
                "id": 141202470,
                "url": "https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...",
                "category": "company",
                "datetime": 1786518635,
                "headline": "West (WST) Stock Looks Overvalued After A 47% One Year Run"
              },
              {
                "id": 141202034,
                "url": "https://finnhub.io/api/news?id=c70632c2f9259acf971a4ff2e21f3a79f70231e7041cbbc36844dbb90356e0cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.",
                "category": "company",
                "datetime": 1786465260,
                "headline": "CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up"
              },
              {
                "id": 141202035,
                "url": "https://finnhub.io/api/news?id=5b2009080943f484ca312cf2ddae85582953343181666e7127ac9f3833e34b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.",
                "category": "company",
                "datetime": 1786461600,
                "headline": "RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised"
              },
              {
                "id": 141177784,
                "url": "https://finnhub.io/api/news?id=2b214d626c55d69f3321fcb009f6866c20e2d848f4d640c809751929b9c57eb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1786380840,
                "headline": "Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut"
              },
              {
                "id": 141176776,
                "url": "https://finnhub.io/api/news?id=51215d10973a1d3873da231aeeefd48c6bc09a21e18da33bfd7c86363e77526d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.",
                "category": "company",
                "datetime": 1786379820,
                "headline": "iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised"
              },
              {
                "id": 141164828,
                "url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
                "category": "company",
                "datetime": 1786243803,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
              },
              {
                "id": 141153743,
                "url": "https://finnhub.io/api/news?id=480497e730b8ea5e3d057667533cf1edc2347a0cb1c86eb68ed0787f76b9527b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Management put a much higher number on its future, and the stock has been on a tear ever since. But is this a fleeting AI boom or a fundamental rewiring of the business.",
                "category": "company",
                "datetime": 1786139750,
                "headline": "Cisco Stock Is Finally Pricing In A New Growth Story"
              },
              {
                "id": 141151192,
                "url": "https://finnhub.io/api/news?id=fc7d6e4a19b1ecefa500bbfc8e2e25de6b5c94dd43bc59e1620796a4007a8a89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.",
                "category": "company",
                "datetime": 1786127700,
                "headline": "XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales"
              },
              {
                "id": 141149609,
                "url": "https://finnhub.io/api/news?id=328e13ad11d15da6764538592fc4d871018f1a757eb98788f0e82e7cddc1f178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.",
                "category": "company",
                "datetime": 1786121220,
                "headline": "AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up"
              },
              {
                "id": 141149610,
                "url": "https://finnhub.io/api/news?id=8e5bd7fa2a58cd02c146fd34fccaed30767229053dcd7376a68126d672047d2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.",
                "category": "company",
                "datetime": 1786120560,
                "headline": "DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up"
              },
              {
                "id": 141140628,
                "url": "https://finnhub.io/api/news?id=a8b9dcae545cc5c62870f85c5a89bc5758dc075833203dde38abaea6245b92f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.",
                "category": "company",
                "datetime": 1786035840,
                "headline": "PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut"
              },
              {
                "id": 141137316,
                "url": "https://finnhub.io/api/news?id=f23c7f57565c87589923985dcfb23a36115479fe932f711cc0df05b80818daf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.",
                "category": "company",
                "datetime": 1786033860,
                "headline": "LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised"
              },
              {
                "id": 141137317,
                "url": "https://finnhub.io/api/news?id=800e586663a06c21846fb4704cde171e522540f493e9141574d3def76d3d7334",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.",
                "category": "company",
                "datetime": 1786030860,
                "headline": "MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised"
              },
              {
                "id": 141135724,
                "url": "https://finnhub.io/api/news?id=8e4664598d306ae1ef59232b19e85e05ac357109829847b04453f423292922d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]",
                "category": "company",
                "datetime": 1786024529,
                "headline": "Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2"
              },
              {
                "id": 141125909,
                "url": "https://finnhub.io/api/news?id=4cc57192c03dfc0eedad44bf9d950f4c8edb9fb26d63e7e6f813fcb1fdc036e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.",
                "category": "company",
                "datetime": 1785952920,
                "headline": "Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?"
              },
              {
                "id": 141124354,
                "url": "https://finnhub.io/api/news?id=3c99f0ca4df1360198bfda8776337250d51ac456a32bc832bac0b78ca6f14858",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.",
                "category": "company",
                "datetime": 1785948000,
                "headline": "HNGE Q2 Earnings Meet Estimates, Sales Top, '26 View Raised, Stock Up"
              },
              {
                "id": 141122656,
                "url": "https://finnhub.io/api/news?id=026d8fb37247e734556ab139d7617d44722f4e154e1c54607e4041ad152a13a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.",
                "category": "company",
                "datetime": 1785941400,
                "headline": "COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised"
              },
              {
                "id": 141122657,
                "url": "https://finnhub.io/api/news?id=d65126c035551814d108e50a1313d81a1237d5b5ba6733964cc3b8dad767605a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.",
                "category": "company",
                "datetime": 1785941340,
                "headline": "FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand"
              },
              {
                "id": 141114964,
                "url": "https://finnhub.io/api/news?id=3a27c79bdda7dbd1818b7e5a6ed33774efec5c2b5603c9fd4a49454d569f3183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.",
                "category": "company",
                "datetime": 1785870540,
                "headline": "RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up"
              },
              {
                "id": 141112034,
                "url": "https://finnhub.io/api/news?id=29220b2023579682d098f84e1a9bd930eeb6b970fa72c6152de3c809aefed06f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.",
                "category": "company",
                "datetime": 1785862680,
                "headline": "Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up"
              },
              {
                "id": 141105188,
                "url": "https://finnhub.io/api/news?id=8445c0043c52e4322380ebeeeaf25c5b1f27d7b1521d55b5c046a500753c77ad",
                "image": "",
                "source": "Fintel",
                "related": "WST",
                "summary": "",
                "category": "company",
                "datetime": 1785810547,
                "headline": "West Pharmaceutical Services (WST) Price Target Increased by 11.46% to 405.03"
              },
              {
                "id": 141102471,
                "url": "https://finnhub.io/api/news?id=30596f6493c7617c08324dee7f0bc7938ac6cda5b78e1147447672994f261dbc",
                "image": "",
                "source": "Benzinga",
                "related": "WST",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $400 to $412.",
                "category": "company",
                "datetime": 1785768764,
                "headline": "Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $412"
              },
              {
                "id": 141097112,
                "url": "https://finnhub.io/api/news?id=ed7760005858daa2fb47089e589aba505882a88fd96abb4b0157752c40e9e312",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...",
                "category": "company",
                "datetime": 1785733722,
                "headline": "Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?"
              },
              {
                "id": 141097113,
                "url": "https://finnhub.io/api/news?id=3672b37da6f185069441e06aab66c46e1ec0c85928bdd57eb6c303fe26995654",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...",
                "category": "company",
                "datetime": 1785731538,
                "headline": "West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?"
              },
              {
                "id": 141087819,
                "url": "https://finnhub.io/api/news?id=440ad6f9856caed08f8f38e51aff99b0e745775dcc353978de6ea663dfb2602f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the compan",
                "category": "company",
                "datetime": 1785596397,
                "headline": "The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call"
              },
              {
                "id": 141086424,
                "url": "https://finnhub.io/api/news?id=3a243f9a49b7b9f0ce5ee608668ded9b9c22573de813e7bfe8c1d840a90af833",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1785575757,
                "headline": "3 Reasons to Avoid WST and 1 Stock to Buy Instead"
              },
              {
                "id": 141084159,
                "url": "https://finnhub.io/api/news?id=b01254886ca04bb4ee2ca13216638f12f5b9bc0c9bbe991af37b4d7b45adc14c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read now.",
                "category": "company",
                "datetime": 1785532692,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 2"
              },
              {
                "id": 141080482,
                "url": "https://finnhub.io/api/news?id=3b0428d64cc3da400032a5c5321ae5b4192319def2ec16d669798ecea40d5a20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
                "category": "company",
                "datetime": 1785516717,
                "headline": "3 Cash-Heavy Stocks We Approach with Caution"
              },
              {
                "id": 141080381,
                "url": "https://finnhub.io/api/news?id=c1245c5746c22ff46ef9ac1ca560e75935767219c3b020b02059cac810c7e881",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.",
                "category": "company",
                "datetime": 1785510480,
                "headline": "MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised"
              },
              {
                "id": 141079192,
                "url": "https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.",
                "category": "company",
                "datetime": 1785504720,
                "headline": "Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141079102,
                "url": "https://finnhub.io/api/news?id=693d7da201dd6ee1737f170709fd5edad838d6fb56b43a75a77dcfa9ba5d0007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.",
                "category": "company",
                "datetime": 1785504660,
                "headline": "SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber Recovery"
              },
              {
                "id": 141077645,
                "url": "https://finnhub.io/api/news?id=5714fc9c6779de656a4e2a6b8b9d2ce3f672f1d8914a60d2ed397cf1fb5e57a1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205618145/image_2205618145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.",
                "category": "company",
                "datetime": 1785487080,
                "headline": "Conestoga SMid Cap Composite Q2 2026 Portfolio Review"
              },
              {
                "id": 141068411,
                "url": "https://finnhub.io/api/news?id=0007ffe0216e700b6c8ed0b3e1049e7206b7730a714da3b4daae9f8b75ec010f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.",
                "category": "company",
                "datetime": 1785427320,
                "headline": "BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract"
              },
              {
                "id": 141068412,
                "url": "https://finnhub.io/api/news?id=cc292e3b8f12ff007275fcb1af654d34bc6fe0a8a71b1d867b4bfd95cdd330fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.",
                "category": "company",
                "datetime": 1785426900,
                "headline": "Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up"
              },
              {
                "id": 141059588,
                "url": "https://finnhub.io/api/news?id=67311e2187c8daa5f97909344e3c76b99fbde905a77e989bccdfea2563d55757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225310528/image_2225310528.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "NOBL beats SPY YTD in 2026; explore 25 undervalued Dividend Aristocrats with 10%+ projected returns and fresh dividend hikes—see the list now.",
                "category": "company",
                "datetime": 1785354040,
                "headline": "Best Dividend Aristocrats For August 2026"
              },
              {
                "id": 141055862,
                "url": "https://finnhub.io/api/news?id=d2c593c9349957b3ca16152323c967c4417d3ab3f9db8797978f488a55bb6f6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.",
                "category": "company",
                "datetime": 1785339720,
                "headline": "GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market"
              },
              {
                "id": 141055863,
                "url": "https://finnhub.io/api/news?id=dc6b208f3d8cb61b19b3c297a8cc56c2951996a4af7af738c66e92cd98982229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.",
                "category": "company",
                "datetime": 1785337380,
                "headline": "Here's Why You Should Retain DaVita Stock in Your Portfolio for Now"
              },
              {
                "id": 141054556,
                "url": "https://finnhub.io/api/news?id=1d05afedea319df981c1c6f83addc02b5f0376cb79960f0906d78929147599c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.",
                "category": "company",
                "datetime": 1785330300,
                "headline": "Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141044101,
                "url": "https://finnhub.io/api/news?id=c8653c2acc661d71ba770d3da529a4053e5cd75994323d7e47a99f7241814252",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.",
                "category": "company",
                "datetime": 1785246180,
                "headline": "STERIS' Q1 Earnings on Deck: What's in Store for the Stock?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 7,
            "recomputed_at_score": true,
            "sentiment_score_raw": 2.1,
            "source_article_count": 63,
            "discarded_article_count": 51
          },
          "sentimentPoints": 8
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 3,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(17.5%→4.9%)；量縮(v10/v30=0.68)；跌縮量(近10日4日)；靠近20日高位；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 682460,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": false,
              "avg_vol_10": 463920,
              "avg_vol_20": 511945,
              "avg_vol_30": 682460,
              "range_pct_10": 0.04857118146807111,
              "range_pct_20": 0.07492276662050645,
              "range_pct_30": 0.17547461845733325,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.6797761040940128,
              "dist_to_20d_high": 0.03941273309243298,
              "down_shrink_days": 4,
              "breakout_level_20d": 360.29001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2767989005765026
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.0335462109109907,
              "turnoverUsdM": 126.50835277785599,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.WST",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 332.0142,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.1,
            "take_profit_price": 363.3945,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2293794881996052,
          "stopLossPercent": 4.0670924218219815,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.WST",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 7.0379,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.03
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -44.41
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0403
    },
    "kdj": {
      "d": 41.73,
      "j": 10.1,
      "k": 31.19,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 37.37
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 8258864,
      "recentSlope": 19516.4,
      "previousSlope": 72730
    },
    "rsi": 38.29,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 359.4967,
      "position": "SAR喺價上",
      "distancePct": 3.87,
      "previousTrend": "下降"
    },
    "ma50": 349.36,
    "macd": {
      "macd": 0.7003355310450843,
      "trend": "中性偏多",
      "signal": 1.0723995350774285,
      "histogram": -0.3720640040323442
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 349.361,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.73,
      "score": 2,
      "avgVolume": 502027,
      "currentVolume": 365536
    },
    "derived": {
      "ma20": 349.6685,
      "ma50": 349.36,
      "prevClose": 349.92,
      "avgVolume10": 422714,
      "avgVolume20": 502027,
      "changePercent": -1.09,
      "avgVolumeForScore": 502027
    },
    "ma_cross": {
      "ma20": 349.6685,
      "ma50": 349.36,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 349.3435,
      "prevMa50": 349.0298,
      "spreadPct": 0.09,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 343.1135,
      "upper": 356.2235,
      "position": "中間"
    },
    "rsi_short": 22.13,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.73
    }
  }
}

{
  "close": 346.09,
  "volume": 365536,
  "changePercent": -1.09
}